Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MARCKS cis regulating lncRNA promoter of cytokines and inflammation (MROCKI)
- Target
- MROCKI
- Molecular classification
- Long non-coding RNA (lncRNA), Other (not a protein—RNA locus)
01
Overview
MARCKS cis regulating lncRNA promoter of cytokines and inflammation (MROCKI) is a cis-acting long non-coding RNA that is induced in human macrophages by Toll-like receptor (TLR) activation. MROCKI regulates the expression of its neighboring gene, MARCKS (myristoylated alanine-rich protein kinase C substrate), by forming a ribonucleoprotein complex with APEX1 at the MARCKS promoter. This complex recruits histone deacetylase HDAC1, leading to changes in chromatin acetylation and suppression of MARCKS transcription. The downstream effects include enhanced production of inflammatory cytokines and chemokines. Genetic variants that influence MROCKI expression are associated with altered risk for several inflammation-related and infection-related diseases, including inflammatory bowel disease and tuberculosis. The lncRNA functions as a master regulator of macrophage innate responses, making it a molecule of interest in studying immune regulation and inflammatory diseases[1][6][8].
- Other names
- LINC01268LOC285758ROCKIRegulator of cytokines and inflammationLong intergenic non-protein coding RNA 1268
02
Mechanism of action
No drugs directly targeting MROCKI; mechanistically, targeting MROCKI would likely modulate inflammatory and cytokine gene expression in immune cells[1][6]
03
Biological functions
Regulation of gene expression, specifically via cis-acting mechanismsModulation of inflammatory responseControl of cytokine and chemokine productionChromatin modification (recruits histone deacetylase HDAC1, affecting promoter H3K27ac status)Modulation of Ca²⁺ signaling in macrophages
04
Disease associations
Inflammation (directly regulates expression of inflammatory cytokines and chemokines[1][6])Infectious disease (regulates innate immune response to pathogens[1])Associations with inflammatory bowel disease and tuberculosis risk (via genetic variants affecting MROCKI expression[1])Cancer (reported links to hepatocellular carcinoma[6])
05
Safety considerations
Potential risks of immune modulation (since MROCKI regulates inflammatory cytokine production, targeting it could risk excessive inflammation or immune suppression)No specific safety data available; concerns are theoretical based on its function[1]
06
Biomarkers
MROCKI expression (potential biomarker for inflammation or susceptibility to infection[1])
Beyond the preview
Go deeper on MARCKS cis regulating lncRNA promoter of cytokines and inflammation (MROCKI).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MARCKS cis regulating lncRNA promoter of cytokines and inflammation (MROCKI).